Cargando…

Dysregulation of COVID-19 related gene expression in the COPD lung

BACKGROUND: Chronic obstructive pulmonary disease (COPD) patients are at increased risk of poor outcome from Coronavirus disease (COVID-19). Early data suggest elevated Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) receptor angiotensin converting enzyme 2 (ACE2) expression, but relati...

Descripción completa

Detalles Bibliográficos
Autores principales: Watson, Alastair, Öberg, Lisa, Angermann, Bastian, Spalluto, C. Mirella, Hühn, Michael, Burke, Hannah, Cellura, Doriana, Freeman, Anna, Muthas, Daniel, Etal, Damla, Belfield, Graham, Karlsson, Fredrik, Nordström, Karl, Ostridge, Kris, Staples, Karl J., Wilkinson, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164067/
https://www.ncbi.nlm.nih.gov/pubmed/34051791
http://dx.doi.org/10.1186/s12931-021-01755-3
_version_ 1783701036409552896
author Watson, Alastair
Öberg, Lisa
Angermann, Bastian
Spalluto, C. Mirella
Hühn, Michael
Burke, Hannah
Cellura, Doriana
Freeman, Anna
Muthas, Daniel
Etal, Damla
Belfield, Graham
Karlsson, Fredrik
Nordström, Karl
Ostridge, Kris
Staples, Karl J.
Wilkinson, Tom
author_facet Watson, Alastair
Öberg, Lisa
Angermann, Bastian
Spalluto, C. Mirella
Hühn, Michael
Burke, Hannah
Cellura, Doriana
Freeman, Anna
Muthas, Daniel
Etal, Damla
Belfield, Graham
Karlsson, Fredrik
Nordström, Karl
Ostridge, Kris
Staples, Karl J.
Wilkinson, Tom
author_sort Watson, Alastair
collection PubMed
description BACKGROUND: Chronic obstructive pulmonary disease (COPD) patients are at increased risk of poor outcome from Coronavirus disease (COVID-19). Early data suggest elevated Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) receptor angiotensin converting enzyme 2 (ACE2) expression, but relationships to disease phenotype and downstream regulators of inflammation in the Renin-Angiotensin system (RAS) are unknown. We aimed to determine the relationship between RAS gene expression relevant to SARS-CoV-2 infection in the lung with disease characteristics in COPD, and the regulation of newly identified SARS-CoV-2 receptors and spike-cleaving proteases, important for SARS-CoV-2 infection. METHODS: We quantified gene expression using RNA sequencing of epithelial brushings and bronchial biopsies from 31 COPD and 37 control subjects. RESULTS: ACE2 gene expression (log2-fold change (FC)) was increased in COPD compared to ex-smoking (HV-ES) controls in epithelial brushings (0.25, p = 0.042) and bronchial biopsies (0.23, p = 0.050), and correlated with worse lung function (r = − 0.28, p = 0.0090). ACE2 was further increased in frequent exacerbators compared to infrequent exacerbators (0.51, p = 0.00045) and associated with use of ACE inhibitors (ACEi) (0.50, p = 0.0034), having cardiovascular disease (0.23, p = 0.048) or hypertension (0.34, p = 0.0089), and inhaled corticosteroid use in COPD subjects in bronchial biopsies (0.33, p = 0.049). Angiotensin II receptor type (AGTR)1 and 2 expression was decreased in COPD bronchial biopsies compared to HV-ES controls with log2FC of –0.26 (p = 0.033) and − 0.40, (p = 0.0010), respectively. However, the AGTR1:2 ratio was increased in COPD subjects compared with HV-ES controls, log2FC of 0.57 (p = 0.0051). Basigin, a newly identified potential SARS-CoV-2 receptor was also upregulated in both brushes, log2FC of 0.17 (p = 0.0040), and bronchial biopsies, (log2FC of 0.18 (p = 0.017), in COPD vs HV-ES. Transmembrane protease, serine (TMPRSS)2 was not differentially regulated between control and COPD. However, various other spike-cleaving proteases were, including TMPRSS4 and Cathepsin B, in both epithelial brushes (log2FC of 0.25 (p = 0.0012) and log2FC of 0.56 (p = 5.49E−06), respectively) and bronchial biopsies (log2FC of 0.49 (p = 0.00021) and log2FC of 0.246 (p = 0.028), respectively). CONCLUSION: This study identifies key differences in expression of genes related to susceptibility and aetiology of COVID-19 within the COPD lung. Further studies to understand the impact on clinical course of disease are now required. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-021-01755-3.
format Online
Article
Text
id pubmed-8164067
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81640672021-06-01 Dysregulation of COVID-19 related gene expression in the COPD lung Watson, Alastair Öberg, Lisa Angermann, Bastian Spalluto, C. Mirella Hühn, Michael Burke, Hannah Cellura, Doriana Freeman, Anna Muthas, Daniel Etal, Damla Belfield, Graham Karlsson, Fredrik Nordström, Karl Ostridge, Kris Staples, Karl J. Wilkinson, Tom Respir Res Research BACKGROUND: Chronic obstructive pulmonary disease (COPD) patients are at increased risk of poor outcome from Coronavirus disease (COVID-19). Early data suggest elevated Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) receptor angiotensin converting enzyme 2 (ACE2) expression, but relationships to disease phenotype and downstream regulators of inflammation in the Renin-Angiotensin system (RAS) are unknown. We aimed to determine the relationship between RAS gene expression relevant to SARS-CoV-2 infection in the lung with disease characteristics in COPD, and the regulation of newly identified SARS-CoV-2 receptors and spike-cleaving proteases, important for SARS-CoV-2 infection. METHODS: We quantified gene expression using RNA sequencing of epithelial brushings and bronchial biopsies from 31 COPD and 37 control subjects. RESULTS: ACE2 gene expression (log2-fold change (FC)) was increased in COPD compared to ex-smoking (HV-ES) controls in epithelial brushings (0.25, p = 0.042) and bronchial biopsies (0.23, p = 0.050), and correlated with worse lung function (r = − 0.28, p = 0.0090). ACE2 was further increased in frequent exacerbators compared to infrequent exacerbators (0.51, p = 0.00045) and associated with use of ACE inhibitors (ACEi) (0.50, p = 0.0034), having cardiovascular disease (0.23, p = 0.048) or hypertension (0.34, p = 0.0089), and inhaled corticosteroid use in COPD subjects in bronchial biopsies (0.33, p = 0.049). Angiotensin II receptor type (AGTR)1 and 2 expression was decreased in COPD bronchial biopsies compared to HV-ES controls with log2FC of –0.26 (p = 0.033) and − 0.40, (p = 0.0010), respectively. However, the AGTR1:2 ratio was increased in COPD subjects compared with HV-ES controls, log2FC of 0.57 (p = 0.0051). Basigin, a newly identified potential SARS-CoV-2 receptor was also upregulated in both brushes, log2FC of 0.17 (p = 0.0040), and bronchial biopsies, (log2FC of 0.18 (p = 0.017), in COPD vs HV-ES. Transmembrane protease, serine (TMPRSS)2 was not differentially regulated between control and COPD. However, various other spike-cleaving proteases were, including TMPRSS4 and Cathepsin B, in both epithelial brushes (log2FC of 0.25 (p = 0.0012) and log2FC of 0.56 (p = 5.49E−06), respectively) and bronchial biopsies (log2FC of 0.49 (p = 0.00021) and log2FC of 0.246 (p = 0.028), respectively). CONCLUSION: This study identifies key differences in expression of genes related to susceptibility and aetiology of COVID-19 within the COPD lung. Further studies to understand the impact on clinical course of disease are now required. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-021-01755-3. BioMed Central 2021-05-29 2021 /pmc/articles/PMC8164067/ /pubmed/34051791 http://dx.doi.org/10.1186/s12931-021-01755-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Watson, Alastair
Öberg, Lisa
Angermann, Bastian
Spalluto, C. Mirella
Hühn, Michael
Burke, Hannah
Cellura, Doriana
Freeman, Anna
Muthas, Daniel
Etal, Damla
Belfield, Graham
Karlsson, Fredrik
Nordström, Karl
Ostridge, Kris
Staples, Karl J.
Wilkinson, Tom
Dysregulation of COVID-19 related gene expression in the COPD lung
title Dysregulation of COVID-19 related gene expression in the COPD lung
title_full Dysregulation of COVID-19 related gene expression in the COPD lung
title_fullStr Dysregulation of COVID-19 related gene expression in the COPD lung
title_full_unstemmed Dysregulation of COVID-19 related gene expression in the COPD lung
title_short Dysregulation of COVID-19 related gene expression in the COPD lung
title_sort dysregulation of covid-19 related gene expression in the copd lung
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164067/
https://www.ncbi.nlm.nih.gov/pubmed/34051791
http://dx.doi.org/10.1186/s12931-021-01755-3
work_keys_str_mv AT watsonalastair dysregulationofcovid19relatedgeneexpressioninthecopdlung
AT oberglisa dysregulationofcovid19relatedgeneexpressioninthecopdlung
AT angermannbastian dysregulationofcovid19relatedgeneexpressioninthecopdlung
AT spallutocmirella dysregulationofcovid19relatedgeneexpressioninthecopdlung
AT huhnmichael dysregulationofcovid19relatedgeneexpressioninthecopdlung
AT burkehannah dysregulationofcovid19relatedgeneexpressioninthecopdlung
AT celluradoriana dysregulationofcovid19relatedgeneexpressioninthecopdlung
AT freemananna dysregulationofcovid19relatedgeneexpressioninthecopdlung
AT muthasdaniel dysregulationofcovid19relatedgeneexpressioninthecopdlung
AT etaldamla dysregulationofcovid19relatedgeneexpressioninthecopdlung
AT belfieldgraham dysregulationofcovid19relatedgeneexpressioninthecopdlung
AT karlssonfredrik dysregulationofcovid19relatedgeneexpressioninthecopdlung
AT nordstromkarl dysregulationofcovid19relatedgeneexpressioninthecopdlung
AT ostridgekris dysregulationofcovid19relatedgeneexpressioninthecopdlung
AT stapleskarlj dysregulationofcovid19relatedgeneexpressioninthecopdlung
AT wilkinsontom dysregulationofcovid19relatedgeneexpressioninthecopdlung
AT dysregulationofcovid19relatedgeneexpressioninthecopdlung